Amount of long-term notes payable classified as other.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Name:	us-gaap_OtherNotesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Commitments and Contingencies (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 30, 2020
Product Liability Contingency [Line Items]
Other Notes Payable	$ 0	$ 0
Aldoxorubicin [Member]
Product Liability Contingency [Line Items]
Amount of milestone payment payable	7,500,000
Arimoclomol [Member]
Product Liability Contingency [Line Items]
Amount of milestone payment payable	3,650,000
Innovivel [Member]
Product Liability Contingency [Line Items]
Future earnout merger consideration	$ 18,300,000